


B1 crd
1652

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH
THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-
CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS,
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON August 23, 2005



Name of Person Mailing the Document

Diane V. Halata

DATE

August 23, 2005

Attorney Docket No. P30693C4X1C1 RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MacPhee, et al.

Serial No.: 09/922,067

Group Art Unit No.: 1652

Filed: August 3, 2001

Examiner: Manjunath N. Rao


For: "Lipoprotein Associated Phospholipase A2 Inhibitors Thereof and Use of the
Same in Diagnosis and Therapy"

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL MAILING TO AN INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

Applicants enclose a copy of the PTO Form 1449 submitted to the USPTO on August 12, 2005, along with copies of the references, except U.S. patent documents, cited therein. Applicants noted in an IDS filed August 12, 2005 that references cited in the PTO Form 1449 would be provided in a supplemental mailing, and thus, include them in this mailing. These references are being mailed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Andrea V. Lockenour
Attorney for Applicants
Registration No. 51,962

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7568
Facsimile (610) 270-5090

N:\AVL\patapps\Lp-PLA2\P30693C4X1C1\Supplemental\Information Disclosure statement.doc

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. P30693C4X1C1 RCE	SERIAL NO. 09/922,067
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT MacPhee, et al.			
		FILING DATE August 3, 2001	GROUP 1652		

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,527,698	6-96	Knopf, et al.			
	AB	5,532,152	7-96	Cousens et al.			
	AC	5,641,669	6-97	Cousens et al.			
	AD	5,981,252	11-99	MacPhee, et al			
	AE	5,968,818	10-99	Gloger, et al.			
	AF	5,840,839	11-98	Wang, et al.			
	AG	10/415,682	05-03	Campbell, et al.			
	AH	11/141,554	05-05	MacPhee, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	BA	0359425 A1	29-08-88	EPO				
	BB	WO89/09818	19-10-89	PCT				
	BC	0509719 A1	21-10-92	EPO				
	BD	WO95/00649	05-01-95	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Chandrakumar NS, et al., "Stereospecific Synthesis of Ether Phospholipids. Preparation of a-Alkyl-2-(acylamino)-2-deoxyglycerophosphoryl cholines," <i>J. Org. Chem.</i> , 1197-1202 (1983)
CB	Ponpipom MM, et al., "Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives," <i>Chem. Phys. Lipids</i> , 35:29-37 (1984)
CC	Stafforini D, et al., "Human plasma platelet-activating factor acetylhydrolase," <i>J. Biol. Chem.</i> 262(9):4223-4230 (1987)
CD	Stafforini D, et al. "Human macrophages secrete plate-activating factor acetylhydrolase," <i>J. Biol. Chem.</i> 265(17):9682-9687 (1990).
CE	Langlais J., et al., Platelet-activating factor acetyl-hydrolase in human semen: a novel decapacitation factor?" <i>Biol. of Reprod.</i> 44 (Suppl.1):94 (1991).
CF	Hong S, et al. "Safety and Short Term Toxicity of a Novel Cationic Lipid Formulation for Human Gene Therapy," <i>Human Gene Therapy</i> :781-798 (1993).
CG	Kim UT, et al. "Synthesis of Phospholipid Headgroups via Nucleophilic Ring Opening of 1,3,2-Dioxaphospholanes," <i>J. Chem. Soc. Chem. Commun.</i> :70-71 (1993).



Sheet 2 of 2.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P30693C4X1C1 RCE	SERIAL NO. 09/922,067
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT MacPhee, et al.	
		FILING DATE Herewith	GROUP 1652

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	Christofferson R, et al. "Ribozymes as Human Therapeutic Agents," <i>J. of Medicinal Chem.</i> : 2023-2037 (1994)
CI	Stull R, et al., "Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects," <i>Pharm. Res.</i> 12(4):465-483(1995)
CJ	Steinbrecher et al., "Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase," <i>J. Lipid Res.</i> , 30(3) :305-315 (1989)
CK	Stremler K E, et al., "An Oxidized Derivative of Phosphatidylcholine is a Substrate for the Platelet-activating Factor Aceylhydrolase from Human Plasma," <i>J. Biol. Chem.</i> , 264(10):5331-5334 (1989)
CL	Sevier ED, et al., "Monoclonal Antibodies in Clinical Immunology," <i>Clinical Chem.</i> 27:1797-1806 (1981)
CM	Kohler G, et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <i>Nature</i> 236:495-497 (August 7, 1975)
CN	Bell, Rachel, et al., "Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control polymorphic variants and case-control analysis in schizophrenia," <i>Biochemical and Biophysical Research Communications</i> , 241(3): 630-635 (1997) XP002197530
CO	Yamada, Yoshiji, et al., "Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese Population", <i>Atherosclerosis</i> , 150(1):209-216(2000) XP002197527
CP	Hiramoto, Maoto, et al., "A mutation in plasma platelet-activating factor acetylhydrolase (Val279fwdarwPhe) is a genetic risk factor for stroke." <i>Stroke</i> , 28(12):2417-2420 (December 12, 1997) XP002197528
CQ	Kruse, Susanne, et al., "The Ile198Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytical activites and are associated with atopy and asthma," <i>Am. Journal of Human Genetics</i> , 66(5):1522-1530 (2000) XP002197529
CR	Tew, D. G., et al., "Purification, properties, sequencing and cloning of a lipo-protein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins", <i>Arteriosclerosis Thrombosis and Vascular Biology</i> , 16(4):591-599 (April, 1996)
CS	Tjoelker, I. W., "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase", <i>Nature, MacMillan Journals Ltd., London</i> , 374(6):549-553 (April 1995) XP002109103
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.